FDA Brief

Warning letters Drugs

FDA warning letter to

Ultra Seal Corporation

High riskIssued Mar 14, 2022Posted Apr 12, 2022Office of Pharmaceutical Quality Operations

FDA warns Ultra Seal and ULTRAtab over manufacturing quality failures in over-the-counter drug cleaning, testing, and release.

What happened

FDA inspected ULTRAtab Toc Drive from August 16 to September 14, 2021, ULTRAtab Riverside from August 24 to September 14, 2021, and Ultra Seal from November 8 to 19, 2021. FDA found incomplete cleaning validation for shared equipment, failing test results that were retested with unvalidated methods until lots passed and were released, and unvalidated or unverified test methods used for release and stability testing. FDA also found uncontrolled electronic data actions such as single injections and deleted methods in lab instrument audit trails, and said Ultra Seal’s quality unit released products despite these testing problems.

What FDA found

  1. The company lacked adequate cleaning procedures and validation for shared equipment, so drug residues could carry over between products.

    21 CFR 211.67(b)
  2. The company did not properly investigate failing or unexplained test results; it retested lots with unvalidated methods until they passed and then released them.

    21 CFR 211.192
  3. The company used many unvalidated or unverified test methods and unreliable Excel calculations for release, stability, and in-process testing.

    21 CFR 211.160(a)
  4. The company did not adequately control lab computer systems; analysts ran unjustified single injections, deleted methods or integrations, and could modify approved test methods.

    21 CFR 211.68(b)
  5. Ultra Seal's quality unit lacked adequate oversight and released drug products based on test results from methods that were not validated or verified.

    21 CFR 211.22(a)

What FDA wants

FDA asks for independent retrospective reviews of cleaning, failing test investigations, lab methods, and electronic data controls, plus remediation plans and actions for products in U.S. distribution, including customer notifications and recalls. The provided letter text does not state a response deadline.

Who should pay attention

  • brands that buy OTC drugs or contract testing from Ultra Seal/ULTRAtab
  • manufacturers whose drugs were tested at ULTRAtab Riverside
  • distributors and retailers selling affected OTC drug lots

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk
  2. Silgan Dispensing Systems

    Silgan Unicep Packaging was cited for manufacturing quality failures and unapproved new drugs after invalidated microbial tests and a fungal recall.

    High risk
  3. Bentley Laboratories LLC

    Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.

    High risk
  4. Stream2Sea, LLC

    FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.

    Medium